

Benign or Concerning? Evidence-Based Strategies for Lung Nodule Workup

Comprehensive Approach to Diagnosis and Treatment

Ghassan Koussa M.D.

Pulmonary and Critical Care Medicine
Oneida Health Pulmonary Specialists



Objectives

1. Identify risk factors and imaging characteristics that distinguish benign from malignant pulmonary nodules.
2. Apply evidence-based risk stratification tools to incidental nodules.
3. Select appropriate follow-up intervals and imaging modalities for low-, intermediate-, and high-risk nodules.
4. Evaluate the role of multidisciplinary discussion.
5. Integrate lung cancer screening criteria for high-risk patients presenting with nodules.

What is a Pulmonary Nodule

Definition

A pulmonary nodule is a rounded or irregular opacity in the lung measuring 3 cm or less in diameter, completely surrounded by pulmonary parenchyma without associated atelectasis or lymphadenopathy.

What is a Pulmonary Nodule

Epidemiology

Pulmonary nodules are frequently detected incidentally on chest CT scans, with a prevalence of up to 50% in high-risk populations. The majority of these nodules are benign, often caused by infections or inflammation.

What is a Pulmonary Nodule

Classification

Nodules are classified based on appearance into three types:

1. Solid.
2. Part-solid.
3. ground-glass or subsolid nodules.

Clinical Challenge

The problem:

- Over 1.5 million incidental pulmonary nodules detected annually in the US alone.
- Most nodules are benign, but a small percentage represent early lung cancer.
- Uncertainty about malignancy risk causes anxiety for patients and providers.
- Lack of clear initial risk stratification can lead to inconsistent management.

Clinical Challenge

The Stakes:

- Excessive imaging and invasive procedures increase patient risk and healthcare costs.
- Delaying diagnosis risks progression of potentially curable lung cancers.
- Over-investigation contributes to patient anxiety and unnecessary radiation exposure.
- Structured guidelines help minimize both under- and over-treatment.

Patient Risk Factors for Malignancy

- **Smoking history.**
- Age.
- Family history.
- Occupational exposures.
- Prior malignancy.
- COPD/Emphysema.

Patient Risk Factors for Malignancy

- Smoking history.
- **Age.**
- Family history.
- Occupational exposures.
- Prior malignancy.
- COPD/Emphysema.

Patient Risk Factors for Malignancy

- Smoking history.
- Age.
- **Family history.**
- Occupational exposures.
- Prior malignancy.
- COPD/Emphysema.

Patient Risk Factors for Malignancy

- Smoking history.
- Age.
- Family history.
- **Occupational exposures.**
- Prior malignancy.
- COPD/Emphysema.

Patient Risk Factors for Malignancy

- Smoking history.
- Age.
- Family history.
- Occupational exposures.
- **Prior malignancy.**
- COPD/Emphysema.

Patient Risk Factors for Malignancy

- Smoking history.
- Age.
- Family history.
- Occupational exposures.
- Prior malignancy.
- **COPD/Emphysema.**

Radiologic Features Suspicious for Malignancy


High risk features:

- **Spiculated or irregular margins.**
- Upper lobe nodules.
- Size greater than 8 mm.
- Part-solid nodules.
- Growth or increase in size.

Patient Name: Anonymous [Hosp ID]
Study Date: [Current Date]

Window/Level: W:1500
Slice: 42

CT Chest Lungs
Slice: 42



Spiculated Nodule (LUL): 1.0 cm

CT Chest Lungs
Slice: 42
Window/Level: L:-600 W:1500

Slice: 42
Window/Level: L:-600 W:1500

Radiologic Features Suspicious for Malignancy

High risk features:

- Spiculated or irregular margins.
- **Upper lobe nodules.**
- Size greater than 8 mm.
- Part-solid nodules.
- Growth or increase in size.

Radiologic Features Suspicious for Malignancy


High risk features:

- Spiculated or irregular margins.
- Upper lobe nodules.
- **Size greater than 8 mm.**
- Part-solid nodules.
- Growth or increase in size.

Radiologic Features Suspicious for Malignancy

High risk features:

- Spiculated or irregular margins.
- Upper lobe nodules.
- Size greater than 8 mm.
- **Part-solid nodules.**
- Growth or increase in size.



Radiologic Features Suspicious for Malignancy

High risk features:

- Spiculated or irregular margins.
- Upper lobe nodules.
- Size greater than 8 mm.
- Part-solid nodules.
- **Growth or increase in size.**

Radiologic Features Suspicious for Malignancy

Lower risk features:

- **Smooth, well-defined margins.**
- Lower lobe nodules.
- Size less than 6 mm.
- Stable nodule size over 2 years.
- Benign calcification patterns (central, popcorn).

Radiologic Features Suspicious for Malignancy


Lower risk features:

- Smooth, well-defined margins.
- **Lower lobe nodules.**
- Size less than 6 mm.
- Stable nodule size over 2 years.
- Benign calcification patterns (central, popcorn).

Radiologic Features Suspicious for Malignancy

Lower risk features:

- Smooth, well-defined margins.
- Lower lobe nodules.
- **Size less than 6 mm.**
- Stable nodule size over 2 years.
- Benign calcification patterns (central, popcorn).



Radiologic Features Suspicious for Malignancy



Lower risk features:

- Smooth, well-defined margins.
- Lower lobe nodules.
- Size less than 6 mm.
- **Stable nodule size over 2 years.**
- Benign calcification patterns (central, popcorn).

Radiologic Features Suspicious for Malignancy

Lower risk features:

- Smooth, well-defined margins.
- Lower lobe nodules.
- Size less than 6 mm.
- Stable nodule size over 2 years.
- **Benign calcification patterns (central, popcorn).**



Management of Solid Nodules < 6 mm

Low risk patients:

No routine follow-up CT scans required.

High risk patient:

12 months follow up CT scan.

Management of Solid Nodules 6-8 mm

Low risk patients:

6-12 months follow-up CT scan.

High risk patient:

6-12 months and 18-24 follow up CT scans.

Management of Solid Nodules > 8 mm

Comprehensive risk assessment.

PET scan evaluation and
tissue sampling.

Management of Subsolid Nodules

- Pure ground glass nodules.
- Part solid nodules.

Management of Subsolid Nodules

Pure ground glass nodules:

- Consider adenocarcinoma in situ or pre-invasive lesion.
- Initial CT done at 6-12 months.
- If stable, annual CT for up to 5 years.

Management of Subsolid Nodules

Part solid nodules:

- Risk is driven by size of solid component.
- Solid component equal to or greater than 6 mm is considered high risk.
- Follow up CT 3-6 months.
- Tissue sampling if any growth is noted.

Role of PET/CT scan

- High sensitivity for nodules larger than 8-10 mm.
- Evaluates for metastatic disease.

False negatives may occur on slow growing tumors.

False positives may occur in inflammatory or infectious disease.

Biopsy Techniques

- CT-guided percutaneous biopsy.
- Navigational bronchoscopy.
- VATS/Surgical resection.

Navigational Bronchoscopy

- 90% diagnostic yield for central nodules.
- 80% diagnostic yield for peripheral nodules.
- Coupled with EBUS bronchoscopy, establishes diagnosis and staging.

Multidisciplinary Teams

Superior clinical outcomes:

- Increased early stage detection.
- Reduction in mortality hazard.
- Guideline concordance.

Streamlined efficiency:

- Single point of care.
- Reduced diagnostic uncertainty.

Liquid biopsy

- Detects circulating tumor DNA.
- Sensitivity limited for early stage or small nodules.

Protein Biomarkers

- Adjunctive risk assessment tool.
- Sensitivity limited for early stage or small nodules.

Referecenes

- MacMahon, H., Naidich, D. P., Goo, J. M., et al. (2017). Guidelines for management of incidental pulmonary nodules detected on CT images: From the Fleischner Society 2017. *Radiology*, 284(1), 228–243. <https://doi.org/10.1148/radiol.2017161659>
- Gould, M. K., Donington, J., Lynch, W. R., et al. (2013). Evaluation of individuals with pulmonary nodules: When is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest*, 143(5 Suppl), e93S–e120S. <https://doi.org/10.1378/chest.12-2351>
- Balasubramanian, P., et al. (2024). Diagnostic yield and safety of diagnostic techniques for pulmonary lesions: Systematic review, meta-analysis and network meta-analysis. *European Respiratory Review*, 33(173), Article 240046. <https://doi.org/10.1183/16000617.0046-2024>



"You have the most adorable lesions in your lungs."

Thank You!